Coeptis Therapeutics Adds Autoimmune Indications To Exclusive License Agreement With University Of Pittsburgh For SNAP-CAR T And SNAP-CAR NK
Coeptis Therapeutics Adds Autoimmune Indications To Exclusive License Agreement With University Of Pittsburgh For SNAP-CAR T And SNAP-CAR NK
Coeptis Therapeutics在與匹茲堡大學簽訂的SNAP-CAR T和SNAP-CAR NK的獨家許可協議中增加了自身免疫適應症
Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR NK cells, has potential to impact various autoimmune diseases in addition to oncology indications.
通用CAR技術平台的專有權利旨在同時靶向多種抗原，該平台最近擴大到包括SNAP-CAR NK細胞，除了腫瘤學適應症外，還可能影響各種自身免疫性疾病。